Prevention of hepatitis B virus-related hepatocellular carcinoma

Abstract

Hepatocellular carcinoma (HCC), especially hepatitis B virus (HBV)-related, remains a major cause of cancer-related mortality worldwide. Unless there is early detection with curative treatment, the 5-year survival rate of advanced HCC is less than 15%. The preventive strategies for HBV-related HCC are thus urgently needed to reduce the global burden of this disastrous cancer. Primary prevention involves the avoidance of viral infection through hepatitis B vaccination and interruption of viral transmission from patients with chronic HBV infection. Universal neonatal hepatitis B vaccination program has successfully reduced the prevalence of HBV carriage rate as well as HCC incidence in vaccinated cohorts. However, HBV elimination is still difficult to achieve. Regarding secondary prevention, long-term treatment with nucleos(t)ide analogues has been proven to reduce the risk of HBV-related HCC. Individual risk stratification and a periodic HCC surveillance in these patients could facilitate early HCC diagnosis. Finally, tertiary prevention can also be achieved by life-long treatment with NAs to reduce the risk of HCC recurrence after curative treatment of primary HCC. Challenges ahead include the fact that HBV is not yet curable by current antiviral agents. Combination therapy with direct anti-HBV agents and host-targeting immunomodulatory agents is under active development. In addition, HCC risk cannot be eliminated even in patients with HBsAg seroclearance or functional cure. Therefore, HCC surveillance is strongly recommended for every patient with chronic HBV infection.

Keywords

Anti-HBV therapy / hepatitis B vaccination / hepatitis B virus / hepatocellular carcinoma

References

[1] Bray F,Soerjomataram I,Torre LA.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries..CA Cancer J Clin2018;68:394-424

[2] Rawla P,Muralidharan P.Update in global trends and aetiology of hepatocellular carcinoma..Contemp Oncol (Pozn)2018;22:141-50 PMCID:PMC6238087

[3] Goossens N,Hoshida Y.Molecular classification of hepatocellular carcinoma: potential therapeutic implications..Hepat Oncol2015;2:371-9 PMCID:PMC4662420

[4] Llovet JM,Sia D.Molecular therapies and precision medicine for hepatocellular carcinoma..Nat Rev Clin Oncol2018;15:599-616

[5] Yang JD,Gores GJ,Plymoth A.A global view of hepatocellular carcinoma: trends, risk, prevention and management..Nat Rev Gastroenterol Hepatol2019;16:589-604 PMCID:PMC6813818

[6] Kao JH.Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia..Liver Int2005;25:696-703

[7] Eslam M,Wong VW.The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease..Hepatol Int2020;

[8] Akinyemiju T,Ahmed M.The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015..JAMA Oncol2017;3:1683-91 PMCID:PMC5824275

[9] Levrero M.Mechanisms of HBV-induced hepatocellular carcinoma..J Hepatol2016;64:S84-101

[10] Nakagawa H,Fujimoto A.Genome sequencing analysis of liver cancer for precision medicine..Semin Cancer Biol2019;55:120-7

[11] Pollicino T,Saffioti F.Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications..J Hepatol2014;61:408-17

[12] Fako V.Kao JH.Molecular carcinogenesis of HBV-related HCC..Hepatitis B virus and liver disease.2018;SingaporeSpringer Nature Singapore Pte Ltd143-62

[13] Chaturvedi VK,Dubey SK,John J.Molecular mechanistic insight of hepatitis B virus mediated hepatocellular carcinoma..Microb Pathog2019;128:184-94

[14] Chen CJ,Su J.Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level..JAMA2006;295:65-73

[15] Yuen MF,Fong DY.Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B..J Hepatol2009;50:80-8

[16] Wong VW,Mo F.Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers..J Clin Oncol2010;28:1660-5

[17] Liu CJ,Chen PJ.Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers..J Infect Dis2006;193:1258-65

[18] Liu CJ,Chen PJ.Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study..J Infect Dis2006;194:594-9

[19] Chen G,Shen F,London WT.Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study..Am J Gastroenterol2006;101:1797-803

[20] Yu MW,Chen PJ.Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men..J Natl Cancer Inst2005;97:265-72

[21] Lin CL.Hepatitis B virus genotypes and variants..Cold Spring Harb Perspect Med2015;5:a021436 PMCID:PMC4448583

[22] Yang HI,Chen PJ.Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma..J Natl Cancer Inst2008;100:1134-43 PMCID:PMC2518166

[23] Lin CL.Natural history of acute and chronic hepatitis B: the role of HBV genotypes and mutants..Best Pract Res Clin Gastroenterol2017;31:249-55

[24] Wong GL,Yiu KK.Meta-analysis: the association of hepatitis B virus genotypes and hepatocellular carcinoma..Aliment Pharmacol Ther2013;37:517-26

[25] Ching LK,Bulkow L.Incidence of hepatocellular carcinoma according to hepatitis B virus genotype in Alaska Native people..Liver Int2016;36:1507-15 PMCID:PMC5021564

[26] Lin C.Clinical Implications of hepatitis B virus variants..J Formos Med Assoc2010;109:321-5

[27] Hsieh YH,Su IJ.Hepatitis B virus pre-S2 mutant large surface protein inhibits DNA double-strand break repair and leads to genome instability in hepatocarcinogenesis..J Pathol2015;236:337-47

[28] Suliman I,Kassamali F.The effects of hepatic steatosis on the natural history of HBV infection..Clin Liver Dis2019;23:433-50

[29] Su HJ,Tseng TC.Pathologic findings of patients with nonalcoholic fatty liver disease and the impact of concurrent hepatitis B virus infection in Taiwan..J Formos Med Assoc2020;119:1476-82

[30] Chan AWH,Chan H.Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B: steatosis and cancer in hepatitis B..J Gastroenterol Hepatol2017;32:667-76

[31] Cho H,Lee JH.Radiologic nonalcoholic fatty liver disease increases the risk of hepatocellular carcinoma in patients with suppressed chronic hepatitis B..J Clin Gastroenterol2020;54:633-41

[32] Abdel-Rahman O,Schöb O.Cigarette smoking as a risk factor for the development of and mortality from hepatocellular carcinoma: an updated systematic review of 81 epidemiological studies..J Evid Based Med2017;10:245-54

[33] Wang YH,Wu CF.Smoking and hepatitis B virus-related hepatocellular carcinoma risk: the mediating roles of viral load and alanine aminotransferase..Hepatology2019;69:1412-25

[34] An P,Yu Y.Host and viral genetic variation in HBV-related hepatocellular carcinoma..Front Genet2018;9:261 PMCID:PMC6060371

[35] Lin CL.Hepatitis B: immunization and impact on natural history and cancer incidence..Gastroenterol Clin North Am2020;49:201-14

[36] World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. WHO Publishers; 2015. Available from: https://www.who.int/hepatitis/publications/hepatitis-b-guidelines/en/. [Last accessed on 30 Sep 2020]

[37] Centers for Disease ControlGlobal Routine Vaccination Coverage, 2010..MMWR2011;60:1520-22

[38] Chen CL,Lin SF.Slow decline of hepatitis B burden in general population: results from a population-based survey and longitudinal follow-up study in Taiwan..J Hepatol2015;63:354-63

[39] Chen DS,Sung JL.A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers..JAMA1987;257:2597-603

[40] Ni YH,Chang MH.Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies..Gastroenterology2007;132:1287-93

[41] Indolfi G,Dusheiko G.Hepatitis B virus infection in children and adolescents..Lancet Gastroenterol Hepatol2019;4:466-76

[42] Chang MH,Chen CJ.Long-term effects of hepatitis B immunization of infants in preventing liver cancer..Gastroenterology2016;151:472-80.e1

[43] Hung GY,Yen HJ,Lin LY.Changing incidence patterns of hepatocellular carcinoma among age groups in Taiwan..J Hepatol2015;63:1390-6

[44] Qu C,Fan C.Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial..PLoS Med2014;11:e1001774 PMCID:PMC4280122

[45] Yeo Y,Kang S.Viral hepatitis and liver cancer in Korea: an epidemiological perspective..Asian Pac J Cancer Prev2013;14:6227-31

[46] McMahon BJ,Singleton RJ.Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program..Hepatology2011;54:801-7

[47] Kao JH.Hepatitis B vaccination and prevention of hepatocellular carcinoma..Best Pract Res Clin Gastroenterol2015;29:907-17

[48] Wen WH,Zhao LL.Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention..J Hepatol2013;59:24-30

[49] Chen HL,Chang CH.Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus..Hepatology2015;62:375-86

[50] Pan CQ,Dai E.Tenofovir to prevent hepatitis B transmission in mothers with high viral load..N Engl J Med2016;374:2324-34

[51] Terrault NA,Mcmahon BJ.Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance..Hepatology2018;67:1560-99 PMCID:PMC5975958

[52] Lampertico P,Berg T.EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection..J Hepatol2017;67:370-98

[53] Splawn L,Medina J.Heplisav-B vaccination for the prevention of hepatitis B virus infection in adults in the United States..Drugs Today2018;54:399

[54] Sarin SK,Lau GK.Asian-pacific clinical practice guidelines on the management of hepatitis B: a 2015 update..Hepatol Int2016;10:1-98 PMCID:PMC4722087

[55] Suk-fong Lok A.Hepatitis B treatment: what we know now and what remains to be researched: hepatology communications..Hepatol Commun2019;3:8-19 PMCID:PMC6312657

[56] Sung JJ,Wong VW,Chan HL.Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma..Aliment Pharmacol Ther2008;28:1067-77

[57] Miyake Y,Yamamoto K.Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection..J Gastroenterol2009;44:470-5

[58] Yang YF,Zhong YD,Shen L.Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis..J Viral Hepat2009;16:265-71

[59] Wong GL,Wong VW,Chan HL.Meta-analysis: reduction in hepatic events following interferon-alfa therapy of chronic hepatitis B..Aliment Pharmacol Ther2010;32:1059-68

[60] Lin CL.Review article: the prevention of hepatitis B-related hepatocellular carcinoma..Aliment Pharmacol Ther2018;48:5-14

[61] Liu K,Le A.Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis..Aliment Pharmacol Ther2019;50:1037-48

[62] Nguyen MH,Le A.Reduced incidence of hepatocellular carcinoma in cirrhotic and noncirrhotic patients with chronic hepatitis B treated with tenofovir-A propensity score-matched study..J Infect Dis2019;219:10-8

[63] Hsu YC,Lee TY.Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir..J Viral Hepat2018;25:543-51

[64] Choi J,Lee J,Ko MJ.Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a korean nationwide cohort study..JAMA Oncol2019;5:30-6 PMCID:PMC6439769

[65] Zhang Z,Yang J,Huang Y.The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis..BMC Cancer2019;19:511 PMCID:PMC6542001

[66] Wu IT,Hung CH.Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study..Clin Microbiol Infect2017;23:464-9

[67] Kim SU,Lee HA.A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea..J Hepatol2019;71:456-64

[68] Lee SW,Lee HL.Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis..Gut2020;69:1301-8 PMCID:PMC7306978

[69] Hsu YC,Chen CH.Tenofovir versus entecavir for hepatocellular carcinoma prevention in an international consortium of chronic hepatitis B..Am J Gastroenterol2020;115:271-80

[70] Tseng C,Chen T.Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis..Lancet Gastroenterol Hepatol2020;5:1039-52

[71] Shin JW,Lee SB.Medication nonadherence increases hepatocellular carcinoma, cirrhotic complications, and mortality in chronic hepatitis B patients treated with Entecavir..Am J Gastroenterol2018;113:998-1008

[72] Rothwell PM,Elwin C.Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials..Lancet2010;376:1741-50

[73] Tsoi KKF,Chan FCH.Long-term use of low-dose aspirin for cancer prevention: a 10-year population cohort study in Hong Kong..Int J Cancer2019;145:267-73

[74] Lee TY,Tseng HC.Association of daily aspirin therapy with risk of hepatocellular carcinoma in patients with chronic hepatitis B..JAMA Intern Med2019;179:633-40 PMCID:PMC6503573

[75] Simon TG,Aleman S,Chan AT.Association of aspirin with hepatocellular carcinoma and liver-related mortality..N Engl J Med2020;382:1018-28

[76] Altwairgi AK.Statins are potential anticancerous agents (review)..Oncol Rep2015;33:1019-39

[77] Hsiang JC,Tse YK,Yip TC.Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis..J Hepatol2015;63:1190-7

[78] Simon TG,Aleman S.Lipophilic statins and risk for hepatocellular carcinoma and death in patients with chronic viral hepatitis: results from a nationwide swedish population..Ann Intern Med2019;171:318-27

[79] Li X,Liu L,Chen Y.Statin and the risk of hepatocellular carcinoma in patients with hepatitis B virus or hepatitis C virus infection: a meta-analysis..BMC Gastroenterol2020;20:98 PMCID:PMC7147033

[80] Yang H,Chan HL.Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score..Lancet Oncol2011;12:568-74

[81] Lee MH,Liu J.Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles..Hepatology2013;58:546-54

[82] Yang HI,Liu J.Incorporating serum level of hepatitis b surface antigen or omitting level of hepatitis B virus DNA does not affect calculation of risk for hepatocellular carcinoma in patients without cirrhosis..Clin Gastroenterol Hepatol2016;14:461-8.e2

[83] Wong GL,Wong CK.Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B..J Hepatol2014;60:339-45

[84] Poh Z,Yang HI.Real-world risk score for hepatocellular carcinoma (RWS-HCC): a clinically practical risk predictor for HCC in chronic hepatitis B..Gut2016;65:887-8

[85] Sinn DH,Kim K.A novel model for predicting hepatocellular carcinoma development in patients with chronic hepatitis B and normal alanine aminotransferase levels..Gut Liver2017;11:528-34 PMCID:PMC5491088

[86] Fan C,Gan Y.A simple AGED score for risk classification of primary liver cancer: development and validation with long-term prospective HBsAg-positive cohorts in Qidong, China..Gut2019;68:948-9

[87] Papatheodoridis G,Sypsa V.PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy..J Hepatol2016;64:800-6

[88] Kim JH,Lee M.Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy..J Hepatol2018;69:1066-73

[89] Sohn W,Kim JH.Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B..Clin Mol Hepatol2017;23:170-8 PMCID:PMC5497662

[90] Chen CH,Lai HC.Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir..Oncotarget2017;8:92431-41 PMCID:PMC5696194

[91] Hsu YC,Ho HJ.Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B..J Hepatol2018;69:278-85

[92] Yu JH,Jin YJ.Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir..Eur J Gastroenterol Hepatol2019;31:865-72

[93] Yang HI,Wong GL.Real-world effectiveness from the Asia pacific rim liver consortium for HBV risk score for the prediction of hepatocellular carcinoma in chronic hepatitis B patients treated with oral antiviral therapy..J Infect Dis2020;221:389-99

[94] Fan R,Sun J.aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis..J Hepatol2020;73:1368-78

[95] Lin CL.Risk stratification for hepatitis B virus related hepatocellular carcinoma..J Gastroenterol Hepatol2013;28:10-7

[96] Bruix J.Management of hepatocellular carcinoma: an update..Hepatology2011;53:1020-2 PMCID:PMC3084991

[97] European Association For The Study Of The Liver, European Organisation For Research And Treatment Of CancerEASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma..J Hepatol2012;56:908-43

[98] Omata M,Kokudo N.Asia-pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update..Hepatol Int2017;11:317-70 PMCID:PMC5491694

[99] Surveillance group, Diagnosis group, Staging group, Surgery group, Local ablation group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting groupManagement consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan..J Formos Med Assoc2018;117:381-403

[100] Trevisani F,Morselli-labate AM.Serum α-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status..J Hepatol2001;34:570-5

[101] Marrero JA,Wang Y.α-Fetoprotein, des-γ carboxyprothrombin, and lectin-bound α-fetoprotein in early hepatocellular carcinoma..Gastroenterology2009;137:110-8 PMCID:PMC2704256

[102] Fu J,Li Z.Clinical utility of decarboxylation prothrombin combined with α-fetoprotein for diagnosing primary hepatocellular carcinoma..Biosci Rep2018;38:BSR20180044 PMCID:PMC6172421

[103] Wang W.Advances in the early diagnosis of hepatocellular carcinoma..Genes Dis2020;7:308-19 PMCID:PMC7452544

[104] Sasaki K,Nishioka Y.Impact of viral etiology on postoperative de novo recurrence after hepatectomy for hepatocellular carcinoma in cirrhotic patients..J Gastrointest Surg2017;21:487-95

[105] Hung IFN,Lai C,Fan S.Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection..The American Journal of Gastroenterology2008;103:1663-73

[106] Wu J,Chau G.Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma..J Hepatol2009;51:890-7

[107] Dan J,Huang J.Hepatitis B virus reactivation after radiofrequency ablation or hepatic resection for HBV-related small hepatocellular carcinoma: a retrospective study..Eur J Surg Oncol2013;39:865-72

[108] Li Z,Xia Y.Association of preoperative antiviral treatment with incidences of microvascular invasion and early tumor recurrence in hepatitis B virus-related hepatocellular carcinoma..JAMA Surg2018;153:e182721 PMCID:PMC6233791

[109] Chen LT,Li LA.Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection..Ann Surg2012;255:8-17

[110] Zhang W,Zhang T.Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: a meta-analysis with comparison of different types of hepatitis..Mol Clin Oncol2014;2:1125-34 PMCID:PMC4179807

[111] Xu J,Chen J.Effect of adjuvant interferon therapy on hepatitis B/C virus-related hepatocellular carcinoma after curative therapy - meta-analysis..Adv Clin Exp Med2015;24:331-40

[112] Yin J,Han Y.Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study..JCO2013;31:3647-55

[113] Huang G,Wang Z.Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial..Ann Surg2015;261:56-66

[114] Wu C,Ho HJ.Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection..JAMA2012;308:1906

[115] Lee T,Zeng Y,Wu M.Association between nucleos(t)ide analog and tumor recurrence in hepatitis B virus-related hepatocellular carcinoma after radiofrequency ablation..Hepatology2016;63:1517-27

[116] Wong GL,Chan HL,Tsoi KK.Oral nucleos(t)ide analogues reduce recurrence and death in chronic hepatitis B-related hepatocellular carcinoma..Aliment Pharmacol Ther2016;43:802-13

[117] Zhang G,Liu P,Jiang X.Efficacy of nucleoside analogs for chronic hepatitis B virus-related hepatocellular carcinoma after curative treatment: a meta-analysis..Dig Dis Sci2018;63:3207-19

[118] Young SH,Lee IC.Aspirin is associated with low recurrent risk in hepatitis B virus-related hepatocellular carcinoma patients after curative resection..J Formos Med Assoc2020;119:218-29

[119] Cho Y,Nam CM.Statin use is associated with decreased hepatocellular carcinoma recurrence in liver transplant patients..Sci Rep2019;9:1467 PMCID:PMC6365496

[120] Kawaguchi Y,Ito D.Statin use is associated with a reduced risk of hepatocellular carcinoma recurrence after initial liver resection..BST2017;11:574-80

[121] Yang H.Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance..Emerg Microbes Infect2019;3:1-7

[122] Zeisel MB,Mason WS.Towards an HBV cure: state-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure..Gut2015;64:1314-26

[123] Lin C.Review article: novel therapies for hepatitis B virus cure - advances and perspectives..Aliment Pharmacol Ther2016;44:213-22

[124] Lang J,Thimme R.Immunological cure of HBV infection..Hepatol Int2019;13:113-24

[125] Smolders EJ,Feld JJ.Review article: clinical pharmacology of current and investigational hepatitis B virus therapies..Aliment Pharmacol Ther2020;51:231-43

[126] Revill PA,Block JM.A global scientific strategy to cure hepatitis B..Lancet Gastroenterol Hepatol2019;4:545-58 PMCID:PMC6732795

[127] Cox AL,Kao J.Progress towards elimination goals for viral hepatitis..Nat Rev Gastroenterol Hepatol2020;17:533-42 PMCID:PMC7376316

[128] Chen YC,Chien RN,Liaw YF.Clinical outcomes after spontaneous and nucleos(t)ide analogue-treated HBsAg seroclearance in chronic HBV infection..Aliment Pharmacol Ther2016;43:1311-8

[129] Kim GA,Kim MJ.Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance..J Hepatol2015;62:1092-9

[130] Kuang XJ,Huo RR.Systematic review of risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance..J Viral Hepat2018;25:1026-37

[131] Yu M,Liu C,Tseng Y.Influence of metabolic risk factors on risk of hepatocellular carcinoma and liver-related death in men with chronic hepatitis B: a large cohort study..Gastroenterology2017;153:1006-17.e5